Please assess the completion status of the following clinical trial:

Trial Title: A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects or female subjects of non childbearing potential~* Total body weight of \>50 kg (110 lbs) and a BMI greater than or equal to 25 kg/m2~* Medical diagnosis of Type 2 Diabetes Mellitus (T2DM) being treated with no more than 1 acceptable oral antidiabetic drug OR Subjects without a diagnosis of T2DM that meet 2 or more of the following 5 criteria commonly associated with metabolic syndrome~  * Fasting Plasma Glucose (FPG) greater than or equal to 100 mg/dL;~ * Documentation of at least stage 1 hypertension or medical history of hypertension;~ * Fasting serum HDL C \<40 mg/dL for males and \<50 mg/dL for females, or on pharmacological agents with explicit purpose to increase HDL-C;~ * Fasting serum triglyceride (TG) greater than or equal to 150 mg/dL or on pharmacological agents with explicit purpose to decrease TG;~ * Waist circumference greater than or equal to 40 inches (102 cm) for males and 35 inches (89 cm) for females.~* Liver fat greater than or equal to 8% measured by MRI PDFF~Exclusion Criteria:~* Subjects with acute or chronic medical or psychiatric condition.~* Subjects with any of the following clinical laboratory abnormalities:~  * Fasting TG \>400 mg/dL;~ * AST, ALT, or GGT \>2.0x ULN;~ * Hemoglobin A1c (HbA1c) \>7.0%;~ * Fasting plasma glucose \>270 mg/dL;~ * Total bilirubin \>1.5x ULN;~ * Albumin \< lower limit of normal (LLN);~ * Platelet count \<0.95x LLN;~ * International normalized ratio (INR) greater than or equal to 1.3.~* A positive urine test for illicit drugs.~* History of regular alcohol consumption.~* Seated systolic BP\>=160 mmHg and/or diastolic BP\>=100 mmHg.~* Supine 12 lead ECG demonstrating a corrected QT (QTcF) interval \>450 msec or a QRS interval \>120 msec.~* Subjects with an estimated GFR \<60 mL/min/1.73m2.~* Evidence or diagnosis of other forms of chronic liver diseases.~* Subjects with any of the following medical conditions:~  * Any condition possibly affecting drug absorption (eg prior bariatric surgery, gastrectomy, ileal resection);~ * Diagnosis of type 1 diabetes mellitus;~ * History of congestive heart failure, unstable angina, myocardial infarction, stroke, or transient ischemic attack;~ * Any malignancy not considered cured (except basal cell carcinoma and squamous cell carcinoma of the skin);~ * Active placement of medical devices in/on thoracic or abdominal cavities such as pacemakers, defibrillators;~* Subjects with any anatomical or pathological abnormality that would either preclude or tend to confound the analysis of study data.~* Blood donation of approximately 1 pint or more within 60 days prior to dosing.~* Subjects taking prohibited concomitant medication(s) or those unwilling/unable to switch to permitted concomitant medication(s)~* Weight loss of greater than or equal to 5% within 1 month prior to Screening.~* Unwilling or unable to comply with the Lifestyle Requirements criteria of the protocol.~* Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential; fertile male subjects who are unwilling or unable to use highly effective method(s) of contraception.~* Investigator site staff members or Pfizer employees, including their family members, directly involved in the conduct of the study.~* Subjects with known prior treatment with or participation in a clinical trial involving any of the IPs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (PF 05221304) BID Placebo (PF 06865571) BID
- PF-05221304 Monotherapy (Type: EXPERIMENTAL): 15 mg PF-05221304 BID Placebo (PF-06865571) BID
- PF-06865571 Monotherapy (Type: EXPERIMENTAL): Placebo (PF-05221304) BID 300 mg PF-06865571 BID
- PF-05221304 and PF-06865571 Combination (Type: EXPERIMENTAL): 15 mg PF-05221304 BID 300 mg PF-06865571 BID

Based on this trial design, predict the completion outcome and termination type (if applicable).